The pharmacophore model-based drug discovery together with the molecular lab-based studies might be useful to facilitate extensive research for other scientists on EGFR mutation through targeting other EGFR-related carcinomas and can be able to find new candidates with a lower toxicity profile. Here, EGFR is linked to carcinoma.